MCID: PRM013
MIFTS: 45

Premature Menopause

Categories: Endocrine diseases, Reproductive diseases

Aliases & Classifications for Premature Menopause

MalaCards integrated aliases for Premature Menopause:

Name: Premature Menopause 12 15 73
Menopause - Premature 12
Menopause, Premature 44
Menopause Premature 55
Menopause Praecox 12

Classifications:



External Ids:

Disease Ontology 12 DOID:10787
ICD10 33 E28.31 E28.319
ICD9CM 35 256.31
MeSH 44 D008594
NCIt 50 C80099
UMLS 73 C0025322

Summaries for Premature Menopause

MalaCards based summary : Premature Menopause, also known as menopause - premature, is related to premature ovarian failure 1 and alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity. An important gene associated with Premature Menopause is BRCA1 (BRCA1, DNA Repair Associated), and among its related pathways/superpathways are DNA Damage and Meiosis. The drugs Progesterone and Estradiol have been mentioned in the context of this disorder. Affiliated tissues include bone, ovary and brain, and related phenotypes are Decreased viability with cisplatin and Synthetic lethal with cisplatin

Related Diseases for Premature Menopause

Diseases related to Premature Menopause via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 89)
# Related Disease Score Top Affiliating Genes
1 premature ovarian failure 1 31.7 AMH SGO2 SYCE1
2 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 30.1 TG TPO
3 thyroiditis 29.7 TG TPO
4 polyneuropathy-intellectual disability-acromicria-premature menopause syndrome 12.2
5 hereditary site-specific ovarian cancer syndrome 10.6 BRCA1 BRCA2
6 breast reconstruction 10.6 BRCA1 BRCA2
7 tuberculous salpingitis 10.6 BRCA1 BRCA2
8 nosophobia 10.6 BRCA1 BRCA2
9 cancerophobia 10.6 BRCA1 BRCA2
10 uterine corpus serous adenocarcinoma 10.6 BRCA1 BRCA2
11 breast-ovarian cancer, familial 1 10.6 BRCA1 BRCA2
12 synchronous bilateral breast carcinoma 10.6 BRCA1 BRCA2
13 fallopian tube adenocarcinoma 10.6 BRCA1 BRCA2
14 peritoneum cancer 10.6 BRCA1 BRCA2
15 glycogen-rich clear cell breast carcinoma 10.6 BRCA1 BRCA2
16 clear cell adenofibroma 10.6 BRCA1 BRCA2
17 lynch syndrome i 10.6 BRCA1 BRCA2
18 dysgerminoma of ovary 10.6 BRCA1 BRCA2
19 bilateral breast cancer 10.6 BRCA1 BRCA2
20 primary peritoneal carcinoma 10.5 BRCA1 BRCA2
21 mutagen sensitivity 10.5 BRCA1 BRCA2
22 pre-malignant neoplasm 10.5 BRCA1 BRCA2
23 fallopian tube carcinoma 10.5 BRCA1 BRCA2
24 ovarian cancer 1 10.5 BRCA1 BRCA2
25 malignant ovarian surface epithelial-stromal neoplasm 10.5 BRCA1 BRCA2
26 ovary epithelial cancer 10.5 BRCA1 BRCA2
27 breast carcinoma in situ 10.5 BRCA1 BRCA2
28 female breast cancer 10.5 BRCA1 BRCA2
29 sporadic breast cancer 10.4 BRCA1 BRCA2
30 ductal carcinoma in situ 10.4 BRCA1 BRCA2
31 hereditary breast ovarian cancer syndrome 10.3 BRCA1 BRCA2
32 familial thyroid dyshormonogenesis 10.3 TG TPO
33 subacute lymphocytic thyroiditis 10.3 TG TPO
34 neonatal hypothyroidism 10.3 TG TPO
35 goiter, multinodular 1, with or without sertoli-leydig cell tumors 10.3 TG TPO
36 endemic goiter 10.3 TG TPO
37 plummer's disease 10.3 TG TPO
38 graves disease 1 10.3 TG TPO
39 hypothyroidism, congenital, nongoitrous, 4 10.3 TG TPO
40 nontoxic goiter 10.3 TG TPO
41 myxedema 10.3 TG TPO
42 toxic diffuse goiter 10.3 TG TPO
43 subacute thyroiditis 10.3 TG TPO
44 female reproductive organ cancer 10.3 BRCA1 BRCA2
45 pernicious anemia 10.3 TG TPO
46 hypothyroidism, thyroidal or athyroidal, with spiky hair and cleft palate 10.3 TG TPO
47 nodular goiter 10.2 TG TPO
48 autoimmune disease of endocrine system 10.2 TG TPO
49 thyroid gland disease 10.1 TG TPO
50 anaplastic thyroid cancer 10.1 TG TPO

Graphical network of the top 20 diseases related to Premature Menopause:



Diseases related to Premature Menopause

Symptoms & Phenotypes for Premature Menopause

GenomeRNAi Phenotypes related to Premature Menopause according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability with cisplatin GR00101-A-4 9.16 BRCA1 BRCA2
2 Synthetic lethal with cisplatin GR00101-A-1 8.96 BRCA1 BRCA2
3 Upregulation of Wnt/beta-catenin pathway after WNT3A stimulation GR00016-A 8.8 BRCA1 BRCA2 SGO2

MGI Mouse Phenotypes related to Premature Menopause:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 9.8 AMH BRCA1 BRCA2 POLG SYCE1 TG
2 homeostasis/metabolism MP:0005376 9.7 BRCA1 BRCA2 POLG SYCE1 TG TPO
3 neoplasm MP:0002006 9.26 AMH BRCA1 BRCA2 POLG
4 reproductive system MP:0005389 9.02 AMH BRCA1 BRCA2 POLG SYCE1

Drugs & Therapeutics for Premature Menopause

Drugs for Premature Menopause (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 188)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Progesterone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 57-83-0 5994
2
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-28-2 5757
3 Estradiol valerate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 979-32-8
4
Ethinyl Estradiol Approved Phase 4,Phase 3,Phase 2,Not Applicable 57-63-6 5991
5
Norethindrone Approved Phase 4,Phase 2,Phase 3,Not Applicable 68-22-4 6230
6
Polyestradiol phosphate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 28014-46-2
7
Ganirelix Approved Phase 4 123246-29-7, 124904-93-4 25081094
8
Leuprolide Approved, Investigational Phase 4,Phase 2 53714-56-0 3911 657181
9
Dopamine Approved Phase 4,Not Applicable 51-61-6, 62-31-7 681
10
Lenograstim Approved, Investigational Phase 4 135968-09-1
11
Lactitol Investigational Phase 4 585-86-4 3871
12 Deslorelin Investigational, Vet_approved Phase 4,Phase 2,Phase 3 57773-65-6
13 Estrogens Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
14 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
15 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
16 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
17 Contraceptive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
18 Contraceptives, Oral Phase 4,Phase 2,Phase 3,Not Applicable
19 Estradiol 17 beta-cypionate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
20 Estradiol 3-benzoate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
21 Norethindrone acetate Phase 4,Phase 2,Phase 3,Not Applicable
22 Norethindrone acetate, ethinyl estradiol, ferrous fumarate drug combination Phase 4
23 Norinyl Phase 4
24 Progestins Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
25 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
26 Luteolytic Agents Phase 4,Phase 3,Phase 2,Not Applicable
27 Triptorelin Pamoate Phase 4,Phase 3,Phase 2,Not Applicable
28 Neurotransmitter Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
29 Adjuvants, Immunologic Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
30 Central Nervous System Stimulants Phase 4,Phase 1,Phase 2,Not Applicable
31 Dopamine Agents Phase 4,Not Applicable
32 Dopamine Uptake Inhibitors Phase 4,Not Applicable
33 Lisdexamfetamine Dimesylate Phase 4,Not Applicable
34 Neurotransmitter Uptake Inhibitors Phase 4,Not Applicable
35
Testosterone Approved, Investigational Phase 3,Phase 2,Phase 1 58-22-0 6013
36
Cyclophosphamide Approved, Investigational Phase 3,Phase 2 50-18-0, 6055-19-2 2907
37
Goserelin Approved Phase 3 65807-02-5 47725 5311128
38
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
39
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
40
Epirubicin Approved Phase 3 56420-45-2 41867
41
Fluorouracil Approved Phase 3 51-21-8 3385
42
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
43
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
44
Gabapentin Approved, Investigational Phase 3 60142-96-3 3446
45
gamma-Aminobutyric acid Approved, Investigational Phase 3 56-12-2 119
46
Triamcinolone Approved, Vet_approved Phase 3 124-94-7 31307
47
Dacarbazine Approved, Investigational Phase 3 4342-03-4 5351166
48
Methylprednisolone Approved, Vet_approved Phase 3,Phase 2 83-43-2 6741
49
Prednisolone Approved, Vet_approved Phase 3,Phase 2 50-24-8 5755
50
Prednisone Approved, Vet_approved Phase 3,Phase 2 53-03-2 5865

Interventional clinical trials:

(show top 50) (show all 194)
# Name Status NCT ID Phase Drugs
1 Effects of ADSC Therapy in Women With POF Unknown status NCT01853501 Phase 4
2 Evaluation of Physiologic and Standard Sex Steroid Replacement Regimens in Women With Premature Ovarian Failure Completed NCT00732693 Phase 4 Ethinylestradiol / Norethisterone;Estradiol / Progesterone
3 Flexible GnRH Antagonist vs Flare up GnRH Agonist Protocol in Poor Responders Completed NCT00417066 Phase 4 Ganirelix 0.25mg (Orgalutran, Organon, The Netherlands);Arvekap 0.1mg (Triptorelin, Ipsen, France)
4 Estrogen Dosing in Turner Syndrome: Pharmacology and Metabolism Completed NCT00837616 Phase 4 17 B estradiol orally;17 B estradiol
5 Long-Term Growth and Skeletal Effects of Early Growth Hormone Treatment in Turner Syndrome Completed NCT00266656 Phase 4 Humatrope
6 Defining the Optimal Hormonal Replacement Therapy in Turner Syndrome Completed NCT00134745 Phase 4 estradiol
7 Growth Response in Girls With Turner Syndrome Completed NCT01734486 Phase 4 somatropin;somatropin
8 Safety of Somatropin and Induction of Puberty With 17-beta-oestradiol in Girls With Turner Syndrome Completed NCT01518062 Phase 4 somatropin;somatropin;somatropin;oestrogen
9 Growth Hormone Treatment for the Prevention of Short Stature in Young Girls With Turner Syndrome Before the Age of 4 Years Completed NCT01066052 Phase 4
10 First Year Growth Response Associated Genetic Markers Validation Phase IV Open-label Study in Growth Hormone Deficient and Turner Syndrome Pre-pubertal Children: the PREDICT Pharmacogenetics Validation Study Completed NCT01419249 Phase 4
11 Predictive Markers in Growth Hormone Deficiency (GHD) and Turner Syndrome (TS) Children Treated With SAIZEN® Completed NCT00256126 Phase 4 Saizen;Saizen
12 Norditropin NordiFlex® Device Compared to the Device Previously Used by Patients or Parents Completed NCT01245374 Phase 4
13 IMProving Executive Function Study Recruiting NCT03187353 Phase 4 Lisdexamfetamine;Placebo oral capsule
14 Evaluation of the Ease of Use, Preference, and Safety of EutropinPen Inj. Recruiting NCT03015909 Phase 4 Somatropin
15 Filgrastim for Premature Ovarian Insufficiency Active, not recruiting NCT02783937 Phase 4 Saline
16 Autologous Bone Marrow Stem Cell Ovarian Transplantation to Restore Ovarian Function in Premature Ovarian Failure Not yet recruiting NCT03535480 Phase 4 G-CSF
17 Effect of Cetrorelex Acetate on Ovarian Function in Women Undergoing Chemotherapy Withdrawn NCT00507780 Phase 4 GnRH antagonist
18 Goserelin in Preventing Early Menopause in Premenopausal Women Undergoing Chemotherapy for Stage I, Stage II, or Stage III Breast Cancer Completed NCT00427245 Phase 3 cyclophosphamide;goserelin acetate
19 Triptorelin in Preventing Early Menopause in Premenopausal Women Who Are Receiving Chemotherapy for Stage I, Stage II, or Stage III Breast Cancer That Has Been Removed By Surgery Completed NCT00311636 Phase 3 cyclophosphamide;docetaxel;doxorubicin hydrochloride;epirubicin hydrochloride;fluorouracil;methotrexate;paclitaxel;triptorelin
20 Efficiency of Gonadotropin-releasing Hormone (GnRH) Agonist in Preventing Chemotherapy Induced Ovarian Failure Completed NCT01160315 Phase 2, Phase 3 Triptorelin;Norethisterone acetate
21 S0230 Goserelin in Preventing Ovarian Failure in Women Receiving Chemotherapy for Breast Cancer Completed NCT00068601 Phase 3 cyclophosphamide;goserelin acetate
22 Pilot Study Comparing Hypnotherapy and Gabapentin for Hot Flashes. Completed NCT00711529 Phase 3 gabapentin
23 Estrogen Treatment (Oral vs. Patches) in Turner Syndrome Completed NCT00140998 Phase 3 17 beta estradiol
24 Administration During Chemotherapy to Reduce Ovarian Failure Following Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer Completed NCT01530607 Phase 3 Standard cyclophosphamide;Goserelin (Zoladex)
25 An Open-Label, Multi-centre, Phase III Study of Local Tolerability of ZOMACTON 10MG Completed NCT00250250 Phase 3 ZOMACTON
26 Combination Chemotherapy in Treating Young Patients With Hodgkin's Lymphoma Completed NCT00433459 Phase 3 cyclophosphamide;dacarbazine;prednisolone;prednisone;procarbazine hydrochloride;vincristine sulfate
27 The Effect of Growth Hormone in Very Young Girls With Turner Syndrome Completed NCT00406926 Phase 3 Somatropin
28 Somatropin Treatment to Final Height in Turner Syndrome Completed NCT00191113 Phase 3 Somatropin;Ethinyl estradiol;Medroxyprogesterone acetate
29 The Effect of Androgen and Growth Hormone on Height and Learning in Girls With Turner Syndrome Completed NCT00029159 Phase 3 estrogen;androgen
30 Induction of Puberty With 17-beta Estradiol in Girls With Turner Syndrome Completed NCT01710696 Phase 3 17-beta estradiol;17-beta estradiol
31 Use of Somatropin in Turner Syndrome Completed NCT01518036 Phase 3 somatropin;somatropin
32 Evaluating Acceptance of New Liquid Somatropin Formulation in Children With Growth Hormone Deficiency Completed NCT01563926 Phase 3 somatropin
33 Study to Define Optimal IGF-1 Monitoring in Children Treated With NutropinAq Completed NCT00234533 Phase 3 Somatropin (rDNA origin)
34 Hormone Replacement for Premature Ovarian Insufficiency Recruiting NCT02922348 Phase 3 Hormone Replacement Therapy;Combined Oral Contraceptives
35 Primary Ovarian Insufficiency: Phenotype and Optimal Treatment Recruiting NCT03568708 Phase 3 Transdermal Estrogen
36 A Clinical Study to Assess the Efficacy and Safety of DA-3002 Active, not recruiting NCT01813630 Phase 3 DA-3002;Genotropin®
37 Dehydroepiandrosterone (DHEA) Treatment and Premature Ovarian Failure (POF) Terminated NCT00948857 Phase 2, Phase 3
38 Effect of Exercise and Phytoestrogen on Bone, Metabolic Syndrome Criteria and Complaints of the Early Menopause Terminated NCT00663104 Phase 3
39 Study of Oral Dehydroepiandrosterone(DHEA) to Treat Previously Unexplained Infertility Terminated NCT00650754 Phase 2, Phase 3
40 Goserelin Acetate Study for Ovarian Function in Patients With Primary Breast Cancer Terminated NCT00429403 Phase 3 Goserelin
41 Stem Cell Therapy Combined Hormone Replacement Therapy in Patients With Premature Ovarian Failure Unknown status NCT01742533 Phase 1, Phase 2 Hormone Replacement Therapy
42 Autologous Mesenchymal Stem Cells Transplantation In Women With Premature Ovarian Failure Unknown status NCT02062931 Phase 1, Phase 2
43 Autologous Stem Cells Transplantation in Patients With Idiopathic and Drug Induced Premature Ovarian Failure Unknown status NCT02043743 Phase 1, Phase 2
44 Chinese Medicine(Hu Yang Yang Kun Formula) for Primary Ovarian Insufficiency Completed NCT02794948 Phase 1, Phase 2
45 Pregnancy After Stem Cell Transplantation in Premature Ovarian Failure Completed NCT02151890 Phase 1, Phase 2
46 "It is a Real" The First Baby Of Autologous Stem Cell Therapy in Premature Ovarian Failure Completed NCT02372474 Phase 1, Phase 2
47 Hormone Replacement in Young Women With Premature Ovarian Failure Completed NCT00001951 Phase 2 TMTDS
48 GnRH Analogue for Ovarian Function Preservation in Hematopoietic Stem Cell Transplantation Patients Completed NCT00429494 Phase 2 Leuprolide Acetate
49 Oxandrolone Compared With a Placebo on Growth Rate in Girls With Growth Hormone-Treated Turner's Syndrome Completed NCT00004275 Phase 2 growth hormone;oxandrolone
50 The Effects of Hormones in Growth Hormone-Treated Girls With Turner Syndrome Completed NCT00001343 Phase 2 Humatrope;Oxandrolone

Search NIH Clinical Center for Premature Menopause

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: menopause, premature

Genetic Tests for Premature Menopause

Anatomical Context for Premature Menopause

MalaCards organs/tissues related to Premature Menopause:

41
Bone, Ovary, Brain, Cortex, Testes, Liver, Bone Marrow

Publications for Premature Menopause

Articles related to Premature Menopause:

(show top 50) (show all 124)
# Title Authors Year
1
Cholesterol profile in women with premature menopause after risk reducing salpingo-oophorectomy. ( 29881922 )
2018
2
Nonsurgical premature menopause and reproductive implications in survivors of childhood cancer: A report from the Childhood Cancer Survivor Study. ( 29338081 )
2018
3
A High-risk Haplotype for Premature Menopause in Childhood Cancer Survivors Exposed to Gonadotoxic Therapy. ( 29432556 )
2018
4
Identifying Biomarkers for Risk of Premature Menopause Among Childhood Cancer Survivors May Lead to Targeted Interventions and Wellness Strategies. ( 29432587 )
2018
5
Ovarian ablation for premenopausal breast cancer: A review of treatment considerations and the impact of premature menopause. ( 28288389 )
2017
6
Prevalence and Determinants of Premature Menopause among Indian Women: Issues and Challenges Ahead. ( 28340231 )
2017
7
Dealing with premature menopause in women at high-risk for hereditary genital and breast cancer. ( 26928421 )
2016
8
Managing premature menopause and sexual dysfunction. ( 26155020 )
2015
9
Hormone treatment may help prevent premature menopause in cancer patients. ( 26702070 )
2015
10
Spanish consensus on premature menopause. ( 25578643 )
2015
11
Prevention of Premature Menopause and Preservation of Fertility in Young Cancer Survivors: Hopeful Though Modest Long-term Results. ( 26720024 )
2015
12
Autosomal Translocation Patient Who Experienced Premature Menopause: A Case Report. ( 26356509 )
2015
13
Premature Menopause. ( 26316242 )
2015
14
Impact of a premature menopause on cognitive function in later life. ( 24802975 )
2014
15
Premature menopause and risk of neurological disease: basic mechanisms and clinical implications. ( 24462786 )
2014
16
Symptoms, health behavior and understanding of menopause therapy in women with premature menopause. ( 24742007 )
2014
17
Risk of premature menopause after treatment for Hodgkin's lymphoma. ( 25139687 )
2014
18
An interpretive description of chemotherapy-induced premature menopause among Latinas with breast cancer. ( 25158665 )
2014
19
Premature menopause - Meeting the needs. ( 24879744 )
2014
20
Risk of premature menopause after treatment for Hodgkin's lymphoma. ( 25139688 )
2014
21
Premature menopause. ( 23634337 )
2013
22
Frequency of premature menopause in women who carry a BRCA1 or BRCA2 mutation. ( 23414920 )
2013
23
Premature menopause in young breast cancer: effects on quality of life and treatment interventions. ( 23819028 )
2013
24
Psychosocial adjustment in women with premature menopause: a cross-sectional survey. ( 22335389 )
2012
25
Premature menopause or early menopause and risk of ischemic stroke. ( 21993082 )
2012
26
Ovarian suppression for prevention of premature menopause and infertility: empty promise or effective therapy? ( 22231046 )
2012
27
A nationwide study on reproductive function, ovarian reserve, and risk of premature menopause in female survivors of childhood cancer: design and methodological challenges. ( 22917040 )
2012
28
Hormone replacement therapy and women with premature menopause--a cancer survivorship issue. ( 21561765 )
2011
29
Premature menopause and severity of coronary artery disease. ( 22279478 )
2011
30
Premature menopause: a comprehensive understanding of psychosocial aspects. ( 21854296 )
2011
31
Premature menopause linked to CVD and osteoporosis. ( 20408329 )
2010
32
Menopause and sexuality: key issues in premature menopause and beyond. ( 20840281 )
2010
33
Premature menopause or early menopause: long-term health consequences. ( 19733988 )
2010
34
Premature menopause is associated with increased risk of cerebral infarction in Japanese women. ( 20042893 )
2010
35
Successful pregnancy with frozen embryo transfer into a gestational carrier from eggs obtained from a woman in premature menopause. ( 19860356 )
2009
36
Premature menopause increases cardiovascular risk. ( 19811237 )
2009
37
Premature menopause: exploring the experience through online communication. ( 19298304 )
2009
38
The concept and treatment methodology for inducing ovulation in women in apparent premature menopause. ( 19688943 )
2009
39
HRT in premature menopause. ( 18796482 )
2008
40
Treatment-related risk factors for premature menopause following Hodgkin lymphoma. ( 17890454 )
2008
41
Ovulation induction and pregnancy in a woman with premature menopause following gonadotropin suppression with the gonadotropin releasing hormone antagonist, cetrorelix--a case report. ( 18404830 )
2008
42
Suspected premature menopause. ( 18403549 )
2008
43
Premature menopause: Hormone replacement therapy is indeed indicated. ( 18497386 )
2008
44
Premature menopause: Article's recommendation of HRT is highly questionable. ( 18467384 )
2008
45
"Coming to grips" with chemotherapy-induced premature menopause. ( 18389434 )
2008
46
Treatment of premature menopause in breast cancer patients. ( 17685250 )
2007
47
Effect of premature menopause on sexuality. ( 19804022 )
2007
48
Management of premature menopause. ( 17448268 )
2007
49
Do survivors of childhood cancer have increased incidence of premature menopause? ( 17259929 )
2007
50
Premature menopause in patients with BRCA1 gene mutation. ( 16773440 )
2006

Variations for Premature Menopause

Expression for Premature Menopause

Search GEO for disease gene expression data for Premature Menopause.

Pathways for Premature Menopause

Pathways related to Premature Menopause according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.8 BRCA1 BRCA2 POLG
2
Show member pathways
11.6 BRCA1 BRCA2 SYCE1
3 9.4 TG TPO

GO Terms for Premature Menopause

Cellular components related to Premature Menopause according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 lateral element GO:0000800 8.62 BRCA1 BRCA2

Biological processes related to Premature Menopause according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell cycle GO:0007049 9.56 BRCA1 BRCA2 SGO2 SYCE1
2 double-strand break repair GO:0006302 9.46 BRCA1 BRCA2
3 intrinsic apoptotic signaling pathway in response to DNA damage GO:0008630 9.43 BRCA1 BRCA2
4 DNA synthesis involved in DNA repair GO:0000731 9.4 BRCA1 BRCA2
5 response to gamma radiation GO:0010332 9.37 BRCA2 POLG
6 strand displacement GO:0000732 9.32 BRCA1 BRCA2
7 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.16 BRCA1 BRCA2
8 hormone biosynthetic process GO:0042446 8.96 TG TPO
9 chordate embryonic development GO:0043009 8.62 BRCA1 BRCA2

Sources for Premature Menopause

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....